Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib Response

被引：0
|
作者：
Radonic, Teodora [1 ]
Geurts-Giele, Willemina R. R. [1 ]
Dubbink, Hendrikus Jan [1 ]
机构：
[1] Erasmus MC Canc Inst, Dept Pathol, Rotterdam, Netherlands
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jtho.2021.05.007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E56 / E56
页数：1
相关论文
共 10 条
  • [1] Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib
    Zhu, Viola W.
    Zhang, Shannon S.
    Zhang, Jian
    Swensen, Jeffrey
    Xiu, Joanne
    Ou, Sai-Hong Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (07) : E51 - E54
  • [2] Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC
    Zhu, Viola W.
    Madison, Russell
    Schrock, Alexa B.
    Ou, Sai-Hong Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (07) : E123 - E126
  • [3] Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation
    Pruis, Melinda A.
    Paats, M. S.
    Geurts, W. R. R.
    Dubbink, H. J.
    Dingemans, A-M C.
    JCO PRECISION ONCOLOGY, 2021, 5 : 849 - 853
  • [4] Reply to "Emergence of High Level of MET Amplification During Treatment With Selpercatinib in KIF5B-RET NSCLC"
    Lin, Jessica J.
    Solomon, Benjamin J.
    JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (07) : E126 - E127
  • [5] Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation
    Zhu, Jinlian
    Chen, Jie
    Liu, Wei
    Zhang, Junling
    Gu, Yulan
    LUNG CANCER-TARGETS AND THERAPY, 2024, 15 : 123 - 128
  • [6] Selpercatinib and capmatinib combination promotes sustained complete response in novel ISOC1-RET fusion lung cancer after resistance to RET inhibitor via MET amplification: Case Report
    Leite, Caio Abner
    Carvalho, Raissa Pierri
    da Costa, Felipe Marques
    Medeiros, Augusto Kreling
    Schutz, Fabio Augusto
    William Jr, William Nassib
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [7] Emergence of MET D1228N mutation as a resistance mechanism following an exceptional response to crizotinib in a MET-amplified triple-negative breast cancer patient
    Parsons, Benjamin M.
    Meier, David R.
    Gurda, Grzegorz T.
    Lofgren, Kristopher A.
    Kenny, Paraic A.
    CANCER RESEARCH, 2018, 78 (13)
  • [8] Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report
    Wang, Yu
    Chen, Zheng
    Han, Xiao
    Li, Jiamei
    Guo, Honglin
    Shi, Junping
    ONCOLOGIST, 2021, 26 (03): : 178 - 181
  • [9] Case report: Salvage capmatinib therapy in KIF5B-MET fusion-positive lung adenocarcinoma with resistance to telisotuzumab vedotin
    Lin, Chien-Yu
    Wei, Sheng-Huan
    Chen, Yi-Lin
    Lee, Chung-Ta
    Wu, Shang-Yin
    Ho, Chung-Liang
    Pavlick, Dean C.
    Su, Po-Lan
    Lin, Chien-Chung
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [10] Case report: Acquired resistance to crizotinib from a MET Y1230H mutation in a patient with non-small cell lung cancer and KIF5B-MET fusion
    Dong, Su-Su
    Dong, Wen
    Tan, Ya-Fen
    Xiao, Qiang
    Wang, Tian-Li
    FRONTIERS IN ONCOLOGY, 2024, 14
1